CA3144900A1 - Nmda receptor constructs to detect and isolate nmdar autoantibodies - Google Patents

Nmda receptor constructs to detect and isolate nmdar autoantibodies Download PDF

Info

Publication number
CA3144900A1
CA3144900A1 CA3144900A CA3144900A CA3144900A1 CA 3144900 A1 CA3144900 A1 CA 3144900A1 CA 3144900 A CA3144900 A CA 3144900A CA 3144900 A CA3144900 A CA 3144900A CA 3144900 A1 CA3144900 A1 CA 3144900A1
Authority
CA
Canada
Prior art keywords
nmdar
protein
autoantibodies
glun1
construct
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3144900A
Other languages
English (en)
French (fr)
Inventor
Hans-Christian Kornau
Harald Pruss
Craig Curtis GARNER
Tanita FREY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
German Center for Neurodegenerative Diseases
Original Assignee
German Center for Neurodegenerative Diseases
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by German Center for Neurodegenerative Diseases filed Critical German Center for Neurodegenerative Diseases
Publication of CA3144900A1 publication Critical patent/CA3144900A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70571—Assays involving receptors, cell surface antigens or cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7095—Inflammation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Peptides Or Proteins (AREA)
  • External Artificial Organs (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3144900A 2019-07-16 2020-07-02 Nmda receptor constructs to detect and isolate nmdar autoantibodies Pending CA3144900A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP19186524.5 2019-07-16
EP19186524 2019-07-16
LULU101308 2019-07-18
LU101308 2019-07-18
PCT/EP2020/068732 WO2021008890A1 (en) 2019-07-16 2020-07-02 Nmda receptor constructs to detect and isolate nmdar autoantibodies

Publications (1)

Publication Number Publication Date
CA3144900A1 true CA3144900A1 (en) 2021-01-21

Family

ID=71143759

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3144900A Pending CA3144900A1 (en) 2019-07-16 2020-07-02 Nmda receptor constructs to detect and isolate nmdar autoantibodies

Country Status (6)

Country Link
US (1) US20230280340A1 (enExample)
EP (1) EP3999850A1 (enExample)
JP (2) JP7659905B2 (enExample)
CN (1) CN114144427A (enExample)
CA (1) CA3144900A1 (enExample)
WO (1) WO2021008890A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120721960A (zh) * 2025-08-19 2025-09-30 上海金域医学检验所有限公司 一种自身免疫性脑炎抗体检测指示试剂、试剂盒与制备工艺

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230280340A1 (en) * 2019-07-16 2023-09-07 Deutsches Zentrum Für Neurodegenerative Erkrankungen E.V. (Dzne) Nmda receptor constructs to detect and isolate nmdar autoantibodies
CN116133684B (zh) 2020-05-27 2025-07-18 阿里亚利斯治疗公司 抗人nr1抗体衍生物
US20240041927A1 (en) * 2020-12-22 2024-02-08 Deutsches Zentrum Für Neurodegenerative Erkrankungen E. V. (Dzne) Chimeric autoantibody receptor (caar) comprising a nicotinic acetylcholine receptor autoantigen
CN114957446B (zh) * 2022-05-31 2023-09-15 陕西脉元生物科技有限公司 与nmdar脑炎患者中的自身抗体结合的nmdar突变体及其构建方法
CN114891091B (zh) * 2022-06-13 2024-04-26 四川携光生物技术有限公司 一种抗nmdar脑炎重组抗原及应用
JPWO2024075803A1 (enExample) * 2022-10-06 2024-04-11
CN116253790A (zh) * 2022-12-13 2023-06-13 迪亚莱博（张家港）生物科技有限公司 一种用于抗nmdar抗体检测的nmdar重组蛋白及其制备方法及其应用
CN116440950B (zh) * 2023-02-24 2023-09-12 华东理工大学 一种催化剂及其制备方法和应用
AU2024242885A1 (en) * 2023-03-30 2025-09-11 Arialys Therapeutics, Inc. Detection of autoantibodies against nr1
KR20260056166A (ko) * 2023-08-01 2026-04-24 메리다 바이오사이언시스, 인크. 자가면역 반응 조절을 위한 분자
CN118566499B (zh) * 2024-08-02 2024-10-08 成都海默云因医学检验实验室有限公司 一种GluN1和GluN2B亚基融合表达检测抗NMDAR抗体的CBA方法及检测试剂
WO2026073156A1 (en) * 2024-09-30 2026-04-02 Arialys Therapeutics, Inc. Detection of autoantibodies against nr1
CN119985969B (zh) * 2024-10-11 2025-11-18 杭州臻源生物医药科技有限公司 一种使用双色荧光检测试剂盒测定抗nmdar抗体的方法
CN122234241B (zh) * 2026-05-22 2026-08-07 杭州宏望生物技术有限公司 一种用于检测nmdar型脑炎自身抗体的融合蛋白及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770460B1 (en) * 1998-01-29 2004-08-03 Wallac Oy Fusion protein and its use in an immunoassay for the simultaneous detection of autoantibodies related to insulin-dependent diabetes mellitus
DE19818790A1 (de) 1998-04-27 1999-10-28 Affina Immuntechnik Gmbh Immunadsorptionsmatrix, Verfahren zu ihrer Herstellung und ihre Verwendung
WO2002026292A1 (de) 2000-09-28 2002-04-04 Affina Immuntechnik Gmbh Durchflussvorrichtung zum trennen von substanzen in körperflüssigkeiten, insbesondere blut und dessen verwendung
US6896872B2 (en) 2001-06-27 2005-05-24 Svetlana A. Dambinova Rapid multiple panel of biomarkers in laboratory blood tests for TIA/stroke
US7932055B2 (en) 2006-06-22 2011-04-26 Novo Nordisk A/S Soluble heterodimeric CD94/NKG2 receptors fusion proteins
EP2057466B1 (en) * 2006-08-15 2013-10-23 The Trustees of the University of Pennsylvania Methods and compositions for treatment and diagnosis of autoimmune encephalitis or epilepsy
DE102010053432A1 (de) * 2010-12-06 2012-06-06 Euroimmun Medizinische Labordiagnostika Ag Verfahren zum Nachweis von anti-NMDA-Rezeptor Autoantikörpern zum Einsatz in Diagnoseverfahren
WO2013041029A1 (en) * 2011-09-23 2013-03-28 Igenimed Pharmaceuticals Inc. Novel soluble ctla4 variants
EP3869198A3 (en) * 2014-03-18 2021-09-22 Sanford Health Reagents and methods for breast cancer detection
GB201409234D0 (en) * 2014-05-23 2014-07-09 Isis Innovation Method
US20230280340A1 (en) 2019-07-16 2023-09-07 Deutsches Zentrum Für Neurodegenerative Erkrankungen E.V. (Dzne) Nmda receptor constructs to detect and isolate nmdar autoantibodies

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120721960A (zh) * 2025-08-19 2025-09-30 上海金域医学检验所有限公司 一种自身免疫性脑炎抗体检测指示试剂、试剂盒与制备工艺

Also Published As

Publication number Publication date
CN114144427A (zh) 2022-03-04
WO2021008890A1 (en) 2021-01-21
JP7875652B2 (ja) 2026-06-18
JP7659905B2 (ja) 2025-04-10
JP2025094198A (ja) 2025-06-24
US20230280340A1 (en) 2023-09-07
JP2022540913A (ja) 2022-09-20
EP3999850A1 (en) 2022-05-25

Similar Documents

Publication Publication Date Title
US20230280340A1 (en) Nmda receptor constructs to detect and isolate nmdar autoantibodies
Pascual-Goñi et al. Antibodies to the Caspr1/contactin-1 complex in chronic inflammatory demyelinating polyradiculoneuropathy
JP6861771B2 (ja) 腎疾患のためのマーカー
CN101925819B (zh) 结核分歧杆菌复合群的免疫检出方法
KR20120096932A (ko) 라임병 항체의 검출을 위한 펩티드 및 방법
KR20140091735A (ko) 라임 질환 항체의 검출을 위한 펩타이드 및 방법
KR20120117778A (ko) 에를리키아 항체의 검출을 위한 펩티드, 장치 및 방법
CN108490174A (zh) 检测car的细胞的方法及其应用
KR20150065744A (ko) 에를리히아 항체의 검출을 위한 펩티드, 장치, 그리고 방법
CA3043662C (en) Analysis of anti-erythrocyte antibody in the presence of antibody directed against a surface-bound erythrocyte antigen
EP3086120A1 (en) Diagnosis of a novel autoimmune disease
Psaridi-Linardaki et al. Specific immunoadsorption of the autoantibodies from myasthenic patients using the extracellular domain of the human muscle acetylcholine receptor α-subunit. Development of an antigen-specific therapeutic strategy
JP2022058619A (ja) 被験体の免疫状態をモニタリングするための改善された方法
WO2019014044A1 (en) ZNT8 AUTO-ANTIGEN BASED ON PROTEOLIPOSOMES FOR THE DIAGNOSIS OF TYPE 1 DIABETES
CN110520736A (zh) 一种功能化生物多层孔隙膜免疫载体、制备方法、应用
CN108508200A (zh) 检测cd19 car的细胞的方法及其应用
JP2592121B2 (ja) ＩｇＡ腎臓病の診断のための方法及びキツト
US4322274A (en) Method of diagnosing cystic fibrosis patients and asymptomatic carrier of the cystic fibrosis gene
CN108779181A (zh) 生产红细胞蛋白质的方法
Seo et al. Sandwich antibody arrays using recombinant antibody-binding protein L
JP7421183B2 (ja) 抗原固相化デバイス
CN114137231B (zh) 一种血型不规则抗体的检测试剂盒及其应用
FI104219B (fi) Diagnostinen menetelmä ja testaustarvikesarja multippeliskleroosin määrittämiseksi
KR102855663B1 (ko) 3d 프린팅을 이용한 신속 면역진단 키트와 그 제조방법
JP2000069963A (ja) アポリポプロテインｅ４特異モノクローナル抗体

Legal Events

Date Code Title Description
D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20241024

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241024

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241025

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250403

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250507

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250626

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250626

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20260213

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20260608

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260618

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260622

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260622